Scinovex
articleTop 1% cited

Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial

JNCI Journal of the National Cancer Institute · 2006 · Vol. 98(9) · pp. 599–609
Robert E. ManselLesley FallowfieldMark KissinAmit GoyalRobert G. NewcombeJ. Michael DixonConstantinos YiangouKieran HorganNigel BundredIan MonypennyDavid EnglandMark SibberingTholkifl I. AbdullahLester BarrU ChettyDudley H. SinnettAnne FleissigDayalan ClarkePeter J. Ell

Abstract

Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.

Breast Cancer Treatment StudiesBreast Lesions and CarcinomasBreast Implant and ReconstructionMedicineSentinel nodeRandomized controlled trialBreast cancerMulticenter trialBiopsyOncologyInternal medicineCancerMulticenter study

MeSH terms

ArmAxillaBreast NeoplasmsDrainageFemaleHumansLength of StayLymph Node ExcisionLymphatic MetastasisLymphedemaMaleMastectomyMiddle AgedMovementQuality of Life
Citations
1,660
FWCI
40.25
field-weighted impact
References
39
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.